Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Conferences

15 Jun 2021

Clinical Operations Strategy Meeting online 2021

14 Jun 2021 - 18 Jun 2021

BIO US 2021 – Digital

31 May 2021

GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

19 May 2021 - 21 May 2021

Advanced Therapies – Virtual

01 May 2021 - 07 May 2021

2021 ARVO Annual Meeting, virtual

22 Mar 2021 - 25 Mar 2021

BioEurope Spring – virtual

17 Apr 2021 - 22 Apr 2021

2021 AAN Annual Meeting, virtual

06 Apr 2021 - 09 Apr 2021

Cell & Gene Meeting on the Mediterranean, virtual

25 Mar 2021

Ophthalmology Future Forums – Asian Retina Virtual Forum

22 Feb 2021 - 25 Feb 2021

4th Annual Gene Therapy for Rare Disorders – virtual

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page